Absolute Neutrophil Count (ANC) Calculator — Neutropenia Severity & Chemo Safety

Calculate ANC from WBC and differential. Grades neutropenia severity (NCI CTCAE), identifies febrile neutropenia risk, and guides chemotherapy dosing decisions.

×10³/μL
%
%
ANC
Neutropenia Severity
Clinical Risk
Extended More scenarios, charts & detailed breakdown
×10³/μL
%
%
ANC
Severity
Risk
Professional Full parameters & maximum detail
×10³/μL
%
%

ANC Result

ANC
Severity

Clinical Decisions

Febrile Neutropenia Assessment
Chemotherapy Dosing Note

How to Use This Calculator

  1. Enter WBC count in ×10³/μL (e.g., 4.5).
  2. Enter neutrophil % and band % from the CBC differential.
  3. ANC, severity grade, and clinical risk display instantly.
  4. Use the Severity Grades tab for NCI CTCAE grading and chemo hold guidance.
  5. The Professional tier assesses febrile neutropenia risk and G-CSF recommendations.

Formula

ANC = WBC (×10³/μL) × (Neutrophils% + Bands%) × 10 = cells/μL. Normal ≥1,500 cells/μL. Febrile neutropenia = ANC <500 + fever ≥38.3°C.

Example

WBC 3.2 ×10³/μL, neutrophils 40%, bands 5%: ANC = 3.2 × 45 × 10 = 1,440 cells/μL — Mild neutropenia (Grade 1).

Frequently Asked Questions

  • The Absolute Neutrophil Count (ANC) is the total number of neutrophils — the primary white blood cells that fight bacterial and fungal infections — present in one microlitre of blood. It is calculated by multiplying the total white blood cell count (WBC) by the combined percentage of segmented neutrophils and band forms from the differential: ANC = WBC (×10³/μL) × (neutrophils% + bands%) / 100. The result is expressed as cells per microlitre. A normal ANC ranges from approximately 1,500 to 7,700 cells/μL in adults, though the lower limit varies slightly by laboratory and age group. ANC is the single most important laboratory value for assessing a patient's susceptibility to infection, particularly bacterial and fungal pathogens. It is routinely monitored during chemotherapy, bone marrow transplantation, and in patients with congenital neutropenia, autoimmune conditions, or aplastic anaemia. Unlike the total WBC, which can be elevated by lymphocytes or monocytes, ANC specifically quantifies the neutrophil compartment responsible for frontline innate immunity.
  • Neutropenia is defined as an ANC below 1,500 cells/μL in adults, and is graded by severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE). Grade 1 (mild) is ANC 1,000–1,499 cells/μL and generally does not require treatment modification. Grade 2 (moderate) is ANC 500–999 cells/μL and carries increased infection risk; antimicrobial prophylaxis and growth factor support may be considered. Grade 3 (severe) is ANC 200–499 cells/μL and warrants hospitalisation if fever develops. Grade 4 (life-threatening, agranulocytosis) is ANC below 200 cells/μL and requires immediate intervention including protective isolation and empiric broad-spectrum antibiotics if any sign of infection is present. In children, the lower limit of normal varies by age: neonates have much higher normal values (up to 26,000 cells/μL), while infants may have a lower limit of 1,000 cells/μL. Some references define severe neutropenia simply as ANC below 500 cells/μL, as this is the threshold below which infection risk rises dramatically.
  • An ANC below 500 cells/μL combined with a temperature of 38.3°C (101°F) or above — or 38.0°C sustained for more than one hour — defines febrile neutropenia, which is a life-threatening oncological emergency. Without intact neutrophil-mediated immunity, bacterial infections can progress from bacteraemia to septic shock within hours. The IDSA Febrile Neutropenia Guidelines (Freifeld 2011) recommend immediate empiric intravenous broad-spectrum antibiotics covering Gram-negative organisms including Pseudomonas aeruginosa — typically piperacillin-tazobactam, cefepime, or a carbapenem. Risk stratification using the MASCC (Multinational Association for Supportive Care in Cancer) score identifies patients who may be managed with oral antibiotics as outpatients versus those requiring inpatient care. The threshold for emergency action applies even without fever if the patient has signs of infection such as rigors, hypotension, or respiratory compromise. ANC below 100 cells/μL (agranulocytosis) carries the highest mortality and mandates immediate haematology consultation regardless of symptoms.
  • ANC is the primary haematological parameter governing chemotherapy administration. Most regimens have protocol-specific ANC thresholds that must be met before each cycle. Typical requirements are ANC ≥1,500 cells/μL for full-dose chemotherapy, though some protocols permit proceeding at ANC ≥1,000 cells/μL with close monitoring. When ANC falls below protocol thresholds, chemotherapy is delayed until recovery or doses are reduced, which can compromise treatment efficacy — particularly in curative-intent regimens for haematological malignancies. Granulocyte colony-stimulating factors (G-CSF) such as filgrastim or pegfilgrastim are used prophylactically or therapeutically to accelerate neutrophil recovery after myelosuppressive chemotherapy. Primary prophylaxis with G-CSF is recommended by ASCO guidelines when the febrile neutropenia risk exceeds 20% with a given regimen. Dose-dense regimens (e.g., biweekly AC-T for breast cancer) routinely require G-CSF support to maintain the accelerated schedule. Anthracycline-containing regimens and platinum-based doublets carry particularly high myelosuppression risk.
  • Benign ethnic neutropenia (BEN) is a well-recognised constitutional variant in which individuals of African, Middle Eastern (particularly Yemenite Jews), and West Indian ancestry have chronically lower ANC values — often in the 500–1,500 cells/μL range — without increased susceptibility to infection or underlying bone marrow pathology. The condition affects approximately 25–50% of individuals of African descent. The mechanism involves reduced mobilisation of the bone marrow neutrophil storage pool rather than reduced production; total neutrophil mass may be normal even when circulating ANC is low. BEN is thought to relate to polymorphisms in the Duffy antigen receptor for chemokines (DARC/ACKR1) gene on red blood cells, which modulates chemokine gradients involved in neutrophil egress. Clinically, it is critical not to misclassify BEN as pathological neutropenia, which could lead to unnecessary diagnostic workup, bone marrow biopsy, or G-CSF treatment. For patients with known BEN, oncologists should adjust chemotherapy hold thresholds accordingly, as standard ANC cutoffs may be inappropriately conservative for these individuals.

Related Calculators

Sources & References (5)
  1. NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 — National Cancer Institute
  2. Freifeld AG et al. — Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer (CID 2011;52:e56-e93) — IDSA
  3. ASCO — Recommendations for the Use of WBC Growth Factors (J Clin Oncol 2015) — ASCO
  4. Hsieh MM et al. — Prevalence of neutropenia in the U.S. population: age, sex, smoking and ethnic differences (Ann Intern Med 2007;146:486-492) — Annals of Internal Medicine
  5. MDCalc — Absolute Neutrophil Count — MDCalc